Skip to main content

Table 2 Outcome assessment (total and by group)

From: A randomized controlled trial comparing lithium plus valproic acid versus lithium plus carbamazepine in young patients with type 1 bipolar disorder: the LICAVAL study

Variable

Li/VPA group

Li/CBZ group

P value

Clinical Global Impressions Scale modified for use in BP (CGI-BP)

  

0.33**

 Week 0, average (standard deviation (SD))

3.8 (1.1)

3.8 (1.1)

 

 Week 8, average, SD

2.7 (1.6)

3.1 (1.5)

 

 Within-group difference, P value*, Cohen’s d

0.001, 0.80

0.057, 0.53

 

CGI-BP - Depression

  

0.89**

 Week 0, average (SD)

3.2 (1.5)

3.5 (1.7)

 

 Week 8, average (SD)

2.1 (1.1)

2.5 (1.6)

 

 Within-group difference P value*, Cohen’s d

0.005, 0.84

0.014, 0.61

 

CGI-BP - Mania

  

0.18**

 Week 0, average (SD)

3.2 (1.7)

2.0 (1.4)

 

 Week 8, average (SD)

2.4 (1.4)

1.9 (1.0)

 

 Within-group difference, P value*, Cohen’s d

0.001, 0.77

0.152, 0.41

 

Depressive symptoms (Hamilton Depression rating Scale)

  

0.36**

 Week 0, average (SD)

19.2 (7.2)

21.6 (7.3)

 

 Week 8, average (SD)

11.3 (7.2)

11.5 (6.0)

 

 Within-group difference, P value*, Cohen’s d

<0.001, 1.10

<0.001, 1.51

 

Manic symptoms (Young Mania Rating Scale)

  

0.68**

 Week 0, average (SD)

11.4 (6.2)

11.1 (5.9)

 

 Week 8, average (SD)

8.7 (5.3)

7.5 (5.2)

 

 Within-group difference, P value*, Cohen’s d

0.041, 0.47

0.023, 0.65

 

Treatment response in 2 months, n (%)

15 (45,5%)

10 (37,0%)

0.61**

Treatment remission in 22 months, n (%)

9 (27.2%)

6 (22.2%)

0.77**

  1. Li/VPA: lithium plus valproic acid group
  2. Li/CBZ: lithium plus carbamazepine group
  3. * Determined by the paired sample t test.
  4. ** Determined by the two-way repeated measures analysis of variance.